13F-HR/A filed by Versant Venture Management, LLC
Versant Venture Management, LLC filed this 13F-HR/A for the quarter ended 2015-12-31, filed 2016-05-05, with 7 holding rows worth $170,904,743.
- Accession
- 0001104659-16-118185
- Filer
- CIK 1560009
- Filed
- 2016-05-05
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q4 2015
A holdings report, amendment of type restatement, 7 entries on the cover page, a total value of $170,904,743 stated on the cover page (in dollars after the unit check, H1), rows summing to $170,904,743 with VALUE read as dollars, detected, 13F file number 028-16849. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| GLAUKOS CORP COM | 377322102 | Stock | 3,136,232 | $77,581,337 | dollars, detected | |
| FIVE PRIME THERAPEUTICS INC. | 33830X104 | Common Stock | 1,092,152 | $45,324,308 | dollars, detected | |
| OCULAR THERAPEUTIX INC | 67576A100 | COM | 2,215,384 | $20,758,148 | dollars, detected | |
| CLOVIS ONCOLOGY INC | 189464100 | COM | 407,416 | $14,259,560 | dollars, detected | |
| ACHAOGEN INC | 004449104 | COM | 1,281,152 | $7,353,812 | dollars, detected | |
| BIOTIE THERAPIES OYJ | 09074D103 | SPONSORED ADR | 268,672 | $3,855,443 | dollars, detected | |
| CYMABAY THERAPEUTICS INC | 23257D103 | COM | 1,048,601 | $1,772,135 | dollars, detected |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001104659-16-095427 | superseded | 2016-02-10 | acceptance time not in the bulk data set | |
| 13F-HR/A 0001104659-16-118185 | this filing | 2016-05-05 | acceptance time not in the bulk data set |